Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy

Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) checkpoint blockade immunotherapy elicits durable antitumor effects in multiple cancers, yet not all patients respond. We report the evaluation of >300 patient samples across 22 tumor types from four KEYNOTE clinica...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Science (American Association for the Advancement of Science) Ročník 362; číslo 6411
Hlavní autori:	Cristescu, Razvan, Mogg, Robin, Ayers, Mark, Albright, Andrew, Murphy, Erin, Yearley, Jennifer, Sher, Xinwei, Liu, Xiao Qiao, Lu, Hongchao, Nebozhyn, Michael, Zhang, Chunsheng, Lunceford, Jared K, Joe, Andrew, Cheng, Jonathan, Webber, Andrea L, Ibrahim, Nageatte, Plimack, Elizabeth R, Ott, Patrick A, Seiwert, Tanguy Y, Ribas, Antoni, McClanahan, Terrill K, Tomassini, Joanne E, Loboda, Andrey, Kaufman, David
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 12.10.2018
Predmet:	Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Biomarkers, Tumor - genetics Cell Cycle Checkpoints Genetic Markers Humans Immunotherapy Inflammation - genetics Molecular Targeted Therapy - methods Mutation Neoplasms - genetics Neoplasms - therapy Programmed Cell Death 1 Receptor - antagonists & inhibitors T-Lymphocytes - immunology Transcriptome Tumor Burden - genetics
ISSN:	1095-9203, 1095-9203
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!